Gemtuzumab Ozogamicin Can Reduce Minimal Residual Disease in Patients With Childhood Acute Myeloid Leukemia

BACKGROUND: Gemtuzumab ozogamicin (GO) is an active agent for the treatment of CD33-postive acute myeloid leukemia (AML) and may improve the outcome of specific patient subgroups when combined with conventional chemotherapy. However, to the best of the authors’ knowledge, the effects of GO on levels...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: O’Hear, Carol, Inaba, Hiroto, Pounds, Stanley, Shi, Lei, Dahl, Gary, Bowman, W. Paul, Taub, Jeffrey W., Pui, Ching-Hon, Ribeiro, Raul C., Coustan-Smith, Elaine, Campana, Dario, Rubnitz, Jeffrey E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4271731/
https://ncbi.nlm.nih.gov/pubmed/24006085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28334
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados